Lin Y - Search Results

1

Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.

Butterfield LH, Vujanovic L, Santos PM, Maurer DM, Gambotto A, Lohr J, Li C, Waldman J, Chandran U, Lin Y, Lin H, Tawbi HA, Tarhini AA, Kirkwood JM. Butterfield LH, et al. Among authors: lin y, lin h. J Immunother Cancer. 2019 Apr 24;7(1):113. doi: 10.1186/s40425-019-0552-x. J Immunother Cancer. 2019. PMID: 31014399 Free PMC article. Clinical Trial.

2

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.

Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, Kirkwood JM. Tarhini AA, et al. Among authors: lin y. J Immunother Cancer. 2015 Sep 15;3:39. doi: 10.1186/s40425-015-0081-1. eCollection 2015. J Immunother Cancer. 2015. PMID: 26380086 Free PMC article.

3

Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab.

Retseck J, VanderWeele R, Lin HM, Lin Y, Butterfield LH, Tarhini AA. Retseck J, et al. Among authors: lin hm, lin y. J Immunother Cancer. 2016 Jun 21;4:38. doi: 10.1186/s40425-016-0141-1. eCollection 2016. J Immunother Cancer. 2016. PMID: 27330811 Free PMC article.

4

Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab.

Najjar YG, Ding F, Lin Y, VanderWeele R, Butterfield LH, Tarhini AA. Najjar YG, et al. Among authors: lin y. J Transl Med. 2017 Feb 21;15(1):39. doi: 10.1186/s12967-017-1140-9. J Transl Med. 2017. PMID: 28222797 Free PMC article. Clinical Trial.

5

Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.

Tarhini A, Lin Y, Lin H, Rahman Z, Vallabhaneni P, Mendiratta P, Pingpank JF, Holtzman MP, Yusko EC, Rytlewski JA, Rao UNM, Ferris RL, Kirkwood JM. Tarhini A, et al. Among authors: lin y, lin h. J Immunother Cancer. 2018 Oct 23;6(1):112. doi: 10.1186/s40425-018-0428-5. J Immunother Cancer. 2018. PMID: 30352626 Free PMC article.

6

CD56^dim CD16^- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α.

Vujanovic L, Chuckran C, Lin Y, Ding F, Sander CA, Santos PM, Lohr J, Mashadi-Hossein A, Warren S, White A, Huang A, Kirkwood JM, Butterfield LH. Vujanovic L, et al. Among authors: lin y. Front Immunol. 2019 Jan 29;10:14. doi: 10.3389/fimmu.2019.00014. eCollection 2019. Front Immunol. 2019. PMID: 30761123 Free PMC article.

7

Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma.

Storkus WJ, Maurer D, Lin Y, Ding F, Bose A, Lowe D, Rose A, DeMark M, Karapetyan L, Taylor JL, Chelvanambi M, Fecek RJ, Filderman JN, Looney TJ, Miller L, Linch E, Lowman GM, Kalinski P, Butterfield LH, Tarhini A, Tawbi H, Kirkwood JM. Storkus WJ, et al. Among authors: lin y. J Immunother Cancer. 2021 Nov;9(11):e003675. doi: 10.1136/jitc-2021-003675. J Immunother Cancer. 2021. PMID: 34782430 Free PMC article. Clinical Trial.

8

Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma.

Tarhini AA, Leng S, Moschos SJ, Yin Y, Sander C, Lin Y, Gooding WE, Kirkwood JM. Tarhini AA, et al. Among authors: lin y. J Immunother. 2012 May;35(4):359-66. doi: 10.1097/CJI.0b013e31825481fe. J Immunother. 2012. PMID: 22495394 Free PMC article. Clinical Trial.

9

A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma.

Tarhini AA, Lin Y, Yeku O, LaFramboise WA, Ashraf M, Sander C, Lee S, Kirkwood JM. Tarhini AA, et al. Among authors: lin y. J Transl Med. 2014 Jan 23;12:19. doi: 10.1186/1479-5876-12-19. J Transl Med. 2014. PMID: 24457057 Free PMC article.

10

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.

Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J, Rao UN, Kirkwood JM. Tarhini AA, et al. Among authors: lin y. PLoS One. 2014 Feb 3;9(2):e87705. doi: 10.1371/journal.pone.0087705. eCollection 2014. PLoS One. 2014. PMID: 24498358 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52,773 results

Search Page

Filters